XML 61 R49.htm IDEA: XBRL DOCUMENT v3.7.0.1
Notes Payable (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Nov. 12, 2015
Jun. 26, 2015
Jan. 22, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Amount of loan obligation       $ 3,618,025   $ 3,618,025   $ 7,471,148
Amortization of debt discount       $ (393,108) $ (868,708)  
Recognized amortization of deferred financing costs       (44,531) (59,224) (88,572) (125,263)  
Unamortized debt issuance cost       74,978   74,978   163,549
Interest expense paid       (187,077) $ (401,958) (434,441) $ (833,222)  
June 26, 2015 Security Agreement [Member] | Quarter Ending September 30, 2015 [Member]                
Debt instrument interest rate percentage   2.00%            
Note payable   $ 250,000            
June 26, 2015 Security Agreement [Member] | June 30, 2016 [Member]                
Note payable   700,000            
June 26, 2015 Security Agreement [Member] | Minimum [Member] | June 30, 2016 [Member]                
Note payable   $ 12,500            
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member]                
Debt instrument interest rate percentage     0.00%          
Note issued as part of asset purchase agreement     $ 1,500,000          
Note maturity date     Jan. 20, 2017          
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2016 [Member]                
Note payable     $ 750,000          
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2017 [Member]                
Note payable     750,000          
Security Agreement [Member] | June 26, 2015 Security Agreement [Member]                
Unamortized debt discount       0   0    
Payments of debt issuance costs       12,500   25,000    
Deferred financing costs       10,486   10,486    
Recognized amortization of deferred financing costs       1,307   2,600    
Interest expense paid       10,365   20,807    
Present value of future payments       286,754   286,754   $ 290,947
Knight Therapeutics Inc [Member] | Loan Agreement [Member]                
Loan amount $ 5,500,000   6,000,000          
Expences associated with loan $ 24,000   $ 40,000          
Debt instrument interest rate percentage 15.00%   15.00%          
Convertible equity offering     $ 1,000,000          
Change in loan interest rate 13.00%   13.00%          
Revenue     $ 13,000,000          
Net income (loss)     $ 2,000,000          
Amount of loan obligation       1,687,500   1,687,500    
Common stock purchase price per share $ 0.49              
Percentage of shares purchaseable under warrants 6.50%              
Deferred financing costs       289,045   289,045    
Recognized amortization of deferred financing costs       14,112   28,070    
Unamortized debt issuance cost       31,792   31,792    
Interest expense paid       83,914   187,654    
Accrued interest expense       0   0    
Note maturity date Nov. 11, 2017              
Warrants term 10 years              
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | ST Warrant [Member]                
Number of warrants to purchase common stock     4,595,187          
Warrants exercise price     $ 1.00          
Beneficial conversion feature of warrants     $ 1,952,953          
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | LT Warrant [Member]                
Number of warrants to purchase common stock     3,584,759          
Warrants exercise price     $ 0.34          
Common stock purchase price per share     $ 1.00          
Percentage of shares purchaseable under warrants     25.00%          
Beneficial conversion feature of warrants     $ 1,462,560          
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrant Shares [Member]                
Number of warrants to purchase common stock 5,550,625              
Amortization of debt discount $ 2,553,287              
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrant Shares One [Member]                
Number of warrants to purchase common stock 4,547,243              
Amortization of debt discount $ 2,067,258              
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | January 22, 2015 Loan One [Member]                
Debt instrument interest rate percentage     5.00%          
Amount of loan obligation     $ 300,000          
Aggregate consideration to be paid     100,000          
Capital expenditures     100,000          
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrants [Member]                
Amount of loan obligation       1,718,750   1,718,750    
Deferred financing costs       233,847   233,847    
Recognized amortization of deferred financing costs       29,111   57,902    
Unamortized debt issuance cost       43,186   43,186    
Interest expense paid       90,234   219,141    
Recognized interest expense       81,758   202,189    
Accrued interest expense       $ 14,127   $ 14,127    
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Origination Fee [Member]                
Expences associated with loan 110,000   120,000          
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Work Fee [Member]                
Expences associated with loan $ 55,000   $ 60,000          
Neuragen Corp [Member] | June 26, 2015 Security Agreement [Member]                
Debt instrument interest rate percentage   0.00%            
Note issued as part of asset purchase agreement   $ 950,000            
Total payments of acquire assets   $ 1,200,000